- $41.98m
- $153.71m
- $29.62m
- 42
- 44
- 87
- 60
Annual income statement for Fibrogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 176 | 235 | 141 | 46.8 | 29.6 |
| Cost of Revenue | |||||
| Gross Profit | 167 | 222 | 120 | 42.8 | 14.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 368 | 524 | 442 | 370 | 180 |
| Operating Profit | -192 | -289 | -301 | -323 | -150 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -189 | -291 | -295 | -323 | -153 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -189 | -291 | -295 | -323 | -153 |
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -189 | -290 | -294 | -284 | -47.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -189 | -290 | -294 | -284 | -47.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -52.7 | -78.5 | -78.4 | -80.9 | -35.1 |